Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Exploring the effects of abacavir on HSP70 modulation of alpha-synuclein-mediated neurodegeneration
FY 2022-23
Summary
Parkinson’s disease (PD) affects around 1 in 500 Canadians over the age of 18. It is characterized by neuron death in the substantia nigra (SN) of the brain, and PD symptoms include tremors, rigidity, and cognitive deficits. PD has no cure, but alpha-synuclein (a-syn) is a protein that can potentially be targeted for treatment. Normally, a-syn is involved in vital neuron functions such as neurotransmitter release. Neuron death occurs when a-syn aggregates, and aggregated a-syn is the main component of Lewy bodies, the characteristic feature of PD. Remarkably, heat shock protein 70 (HSP70), a protein that regulates protein formation, reduces aggregated a-syn. Our lab has shown that abacavir, a treatment for human immunodeficiency virus, increases HSP70, decreases aggregated a-syn, and lessens neuron death in cells and in worms. Next, we will test abacavir in a mammalian rat model. We hypothesize that abacavir will reduce a-syn-mediated neuron death by increasing HSP70. We aim to evaluate abacavir’s efficacy, effect on HSP70, and brain penetration. The SN of adult rats will be injected with a virus that induces expression of human mutant A53T a-syn or with a control. Then, they will be given abacavir or a control substance daily for five weeks. After the rats are sacrificed, we will determine the level of neuron death, a-syn, and HSP70 in the SN, and measure the concentration of abacavir in blood, cerebrospinal fluid, and brain tissue. We expect abacavir-treated groups to show less neuron death, less aggregated a-syn, and more HSP70 than controls. We also expect high penetration of abacavir into the central nervous system. Overall, this study may advance abacavir towards the clinic where it could improve the lives of the hundreds of thousands affected by PD across Canada.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486151
Name
Tan Cherisse G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the effects of abacavir on HSP70 modulation of alpha-synuclein-mediated neurodegeneration
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Abacavir; Alpha-Synuclein; Drug Repurposing; Hsp70; Neurodegeneration; Parkinon'S Disease
Abstract
Parkinson’s disease (PD) affects around 1 in 500 Canadians over the age of 18. It is characterized by neuron death in the substantia nigra (SN) of the brain, and PD symptoms include tremors, rigidity, and cognitive deficits. PD has no cure, but alpha-synuclein (a-syn) is a protein that can potentially be targeted for treatment. Normally, a-syn is involved in vital neuron functions such as neurotransmitter release. Neuron death occurs when a-syn aggregates, and aggregated a-syn is the main component of Lewy bodies, the characteristic feature of PD. Remarkably, heat shock protein 70 (HSP70), a protein that regulates protein formation, reduces aggregated a-syn. Our lab has shown that abacavir, a treatment for human immunodeficiency virus, increases HSP70, decreases aggregated a-syn, and lessens neuron death in cells and in worms. Next, we will test abacavir in a mammalian rat model. We hypothesize that abacavir will reduce a-syn-mediated neuron death by increasing HSP70. We aim to evaluate abacavir’s efficacy, effect on HSP70, and brain penetration. The SN of adult rats will be injected with a virus that induces expression of human mutant A53T a-syn or with a control. Then, they will be given abacavir or a control substance daily for five weeks. After the rats are sacrificed, we will determine the level of neuron death, a-syn, and HSP70 in the SN, and measure the concentration of abacavir in blood, cerebrospinal fluid, and brain tissue. We expect abacavir-treated groups to show less neuron death, less aggregated a-syn, and more HSP70 than controls. We also expect high penetration of abacavir into the central nervous system. Overall, this study may advance abacavir towards the clinic where it could improve the lives of the hundreds of thousands affected by PD across Canada.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tan, Cherisse G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~